Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) - Clinicopathological features based on the data of two hungarian lymphoma centres

Pathology and Oncology Research

Volumn 14, Issue 4, 2008, Pages 411-421

  Illes A ^a   Simon, Zs ^a   Toth E ^b   Rosta, A ^b   Miltényi, Zs ^a   Molnár, Zs ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Classical hodgkin lymphoma; Differential diagnosis; Immunohistochemistry; Nodular lymphocyte predominant hodgkin lymphoma; Treatment, prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CENTER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; HUNGARY; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; MIDDLE AGED; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 60049089621     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9043-y     Document Type: Article

References (45)

1. Jackson H (1937) Classification and prognosis of Hodgkin's disease and allied disorders. Surg Gynecol Obstet 64:465
2. Jackson H, Parker F (1944) Hodgkin's disease. I. General considerations. N Eng J Med 230:35-44
3. Lukes RJ, Butler JJ (1966) The pathology and nomenclature of Hodgkin's disease. Cancer Res 26:1063-1083
4. Lukes RJ, Butler JJ, Hicks EB (1966) Natural history of Hodgkin's disease as related to its pathologic picture. Cancer 19:317
5. Tsai HK, Mauch PM (2007) Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Rad Oncol 17:184-189
6. Harris NL, Jaffe ES, Stein H, et al (1994) A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361-1362
7. Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization Classification of neoplastic diseases of hematopoetic and lymphoid tissues: Report of the Clinical Advisory Commitee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
8. Nogová L, Rudiger T, Engert A (2006) Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006:266-272
9. Diehl V, Sextro M, Franklin J et al (1999) Clinical presentation, course and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17:776-783
10. Hicks J, Flaitz C (2002) Progressive transformation of germinal centers: review of histopathologic and clinical features. Int J Ped Otorhinolar 65:195-202
11. Boudová L, Torlakovic E, Delabie J et al (2003) Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 102(10):3753-3758
12. Lister TA, Crowther D, Sutcliffe SB, et al (1989) Report of a committee convened to discuss the evolution and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636
13. Tubiana M, Henry-Amar M, Carde P, et al (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 73(l):47-56
14. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin's disease. N Eng J Med 339:1506-1514
15. Varga Gy et al (1998) Hodgkin's disease. Magy Belorv Arch 2 (suppl.):80-81
16. Illés Á, Udvardy M, Ésik O, et al (2004) Hodgkin's disease (HL). In: Lehoczky D (ed) Hematológiai betegségek kezelésének módszertana. Documed, Budapest, pp 133-140
17. Illés Á, Keresztes K, Miltényi Zs et al (2004) Epidemiologic and treatment data on Hodgkin's disease in Hungary - report of the Hodgkin's Disease Work Group. Hematol-Transzfuziol 37:153-163
18. Jaffe E, Harris NL, Stein H et al (2001) Pathology and genetics of tumors of haematopoetic and lymphoid tissues. IARC, Lyon, France pp 240-243
19. + T-cell populations in nodular lymphocyte predominant Hodgkin lymphoma: further charachterization and relationship to other entities. Haematologica Suppl 5:2
20. Harris NL (1998) The many faces of Hodgkin's disease around the world: what have we learned from its pathology? Ann Oncol 9 (5):S45-S56
21. Pajor L (2002) Hodgkin lymphomas: current presentation of pathogenesis and patomorphology. Orv Hetil 143(13):651-661
22. Wang SA, Olson N, Zukerberg L et al (2006) Splenic marginal zone lymphoma with micronodular T-cell rich B-cell lymphoma. Am J Surg Pathol 30:128-132
23. Dogan A, Burke JS, Goteri G et al (2003) Micronodular T-cell/histiocyte-rich large B-cell lymphoma of the spleen. Histology, immunophenotype and differential diagnosis. Am J Surg Pathol 27:903-911
24. Fekete S, Matolcsy A (1998) A Hodgkin-kór es a non-Hodgkin lymphoma határterületei. In: Pálóczi K, Kelényi G (eds) Non- Hodgkin lymphoma. Springer, Budapest, pp 284-289
25. Fan Z, Natkunam Y, Bair E et al (2003) Characterization of variant patterns of nodular lymphocyte predominant Hodgkin- lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 27(10):1346-1356
26. Nogova L, Reineke T, Josting A, et al (2005) Lymphocyte predominant and classical Hodgkin's lymphoma-comparison of outcomes. Eur J Hematol Suppl 66:106-110
27. Diehl V, Engert A, Re D (2007) New Strategies for the treatment of advanced-stage Hodgkin's lymphoma. Hematol Oncol Clin N Am 21:897-914
28. Cosset JM, Henry-Amar M, Meerwaldt JH (1991) Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 2 (Suppl.2):77-82
29. Hutchings M, Loft A, Hansen M (2006) Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24:146-150
30. Wirth A, Yuen K, Barton M (2005) Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australian Radiation Oncology Lymphoma Group. Cancer 104:1221-12229
31. Nogova L, Reineke T, Eich HT (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage LA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from German Hodgkin Study Group (GHSG). Ann Oncol 16:1683-1687
32. Wilder RB, Schlembach PJ, Jones D (2002) European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94:1731-1738
33. Savage KJ, Hoskins P, Klasa R et al (2007) ABVD chemotherapy is essential for optimal treatment of limited stage nodular lymphocyte predominant Hodgkin lymphoma. Hematology Suppl 5:27
34. Müller RP, Eich HT (2007) Dose and field size, the GSHG experience. Hematology Suppl 5:18
35. Ekstrand BC, Lucas JB, Horwitz SM, et al (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101:4285-4289
36. Schulz H, Rehwald U, Morschhauser F et al (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase-II trial by German Hodgkin Lymphoma Study Group (GHSG). Blood 1:109-111
37. Younes A, Fayad LY, Goy A, et al (2006) Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: improvement of event free survival (EFS) in all international prognostic score (IPS) groups [abstract]. Blood 108:2742
38. Younes A, Fayad LY, Goy A et al (2007) Phase-II study of rituximab plus ABVD for the treatment of newly diagnosed patients with advanced stage classical Hodgkin lymphoma (HL). Hematology Suppl 5:33
39. Ambinder RF, Jones RJ, Matsui W (2007) Hodgkin's lymphoma (HL): evidence for a cancer stem cell and therapeutic implications. Hematology Suppl 5:12
40. Wickert RS, Weisenburger DD, Tierens A et al (1995) Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 86:2312-2320
41. Greiner TC, Gascoyne RD, Anderson ME et al (1996) Nodular lymphocyte-predominant Hodgkin's disease associated with large- cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 88:657-666
42. Mathas S (2007) The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity. Hematol Oncol Clin N Am 21:787-804
43. Mittal BB, Nalesnik M, Composite (1986) lymphoma (Hodgkin's and non-Hodgkin's) of the spleen in a previously untreated patient. Acta Hematol 76:29-32
44. Sundeen JT, Cossman J, Jaffe ES (1988) Lymphocyte predominant Hodgkin's disease nodular subtype with coexistent 'large cell lymphoma'. Histological progression or composite malignancy? Am J Surg Pathol 12:599-606
45. Huang JZ, Weisenburger DD, Vose JM, et al (2004) Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymph 45:1551-1557